tbuckley/cabot-search huggingface dataset:
AB0519 THE ASSOCIATION OF LARGE JOINT INVOLVEMENT AT THE START OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND JANUS KINASE INHIBITORS WITH DISEASE ACTIVITY AND DRUG RETENTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ANSWER COHORT STUDY
Authors: I. Shirasugi, A. Onishi, K. Nishimura, W. Yamamoto, K. Murakami, H. Onizawa, Y. Maeda, K. Ebina, Y. Son, H. Amuro, M. Katayama, R. Hara, K. Nagai, Y. Hiramatsu, M. Hashimoto, T. Okano, T. Maeda, S. Hayashi, S. Jinno, Y. Yamamoto, H. Yamada, S. Sendo, Y. Ueda, J. Saegusa
Journal: Annals of the Rheumatic Diseases (2024)
Circular RNA hsa_circ_0000467 promotes colorectal cancer progression by promoting eIF4A3-mediated c-Myc translation
Authors: Xianjie Jiang, Mingjing Peng, Qiang Liu, Qiu Peng, Linda Oyang, Shizhen Li, Xuemeng Xu, Mengzhou Shen, Jiewen Wang, Haofan Li, Nayiyuan Wu, Shiming Tan, Jinguan Lin, Longzheng Xia, Yanyan Tang, Xia Luo, Qianjin Liao, Yujuan Zhou
Journal: Molecular Cancer (2024)

Colorectal cancer (CRC) is the second most common malignant tumor worldwide, and its incidence rate increases annually. Early diagnosis and treatment are crucial for improving the prognosis of patients with colorectal cancer. Circular RNAs are noncoding RNAs with a closed-loop structure that play a significant role in tumor development. However, the role of circular RNAs in CRC is poorly understood.
Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer
Authors: Hong-Xiang Shi, Hang-Tian Tao, Jin-Jin He, Feng-Yi Zhu, Cui-Qing Xie, Yu-Na Cheng, Li-Li Hou, Hua Sun, Chang-Jiang Qin, Dong Fang, Song-Qiang Xie
Journal: Molecular Cancer (2024)

Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibitor targeting PD-1/PD-L1 was only used to treat a small proportion of metastatic triple-negative breast cancer (TNBC), and the clinical outcomes was very limited. In addition, this regimen cannot prevent paclitaxel-induced peripheral neuropathy. Therefore, there was an urgent need for a novel target to enhance the antitumor activity of paclitaxel and alleviate chemotherapy-induced peripheral neuropathy in breast cancer. Here, we found that Dickkopf-1 (DKK1) expression was upregulated in multiply subtypes of human breast cancer specimens after paclitaxel-based chemotherapy. Mechanistic studies revealed that paclitaxel promoted DKK1 expression by inducing EGFR signaling in breast cancer cells, and the upregulation of DKK1 could hinder the therapeutic efficacy of paclitaxel by suppressing the infiltration and activity of CD8+ T cells in tumor microenvironment. Moreover, paclitaxel treatment in tumor-bearing mice also increased DKK1 expression through the activation of EGFR signaling in the primary sensory dorsal root ganglion (DRG) neurons, leading to the development of peripheral neuropathy, which is charactered by myelin damage in the sciatic nerve, neuropathic pain, and loss of cutaneous innervation in hindpaw skin. The addition of an anti-DKK1 antibody not only improved therapeutic efficacy of paclitaxel in two murine subtype models of breast cancer but also alleviated paclitaxel-induced peripheral neuropathy. Taken together, our findings providing a potential chemoimmunotherapy strategy with low neurotoxicity that can benefit multiple subtypes of breast cancer patients.
Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms
Authors: Dragan Jevremovic, Min Shi, Pedro Horna, Gregory E. Otteson, Michael M. Timm, Linda B. Baughn, Patricia T. Greipp, Wilson I. Gonsalves, Prashant Kapoor, Morie A. Gertz, Moritz Binder, Francis K. Buadi, Jiehao Zhou, Angela Dispenzieri, Taxiarchis Kourelis, Eli Muchtar, S. Vincent Rajkumar, Shaji K. Kumar, Horatiu Olteanu
Journal: Blood Cancer Journal (2024)
Cognitive causes of ‘like me’ race and gender biases in human language production
Authors: Jessica Brough, Lasana T. Harris, Shi Hui Wu, Holly P. Branigan, Hugh Rabagliati
Journal: Nature Human Behaviour (2024)

Abstract Natural language contains and communicates social biases, often reflecting attitudes, prejudices and stereotypes. Here we provide evidence for a novel psychological pathway for the expression of such biases, in which they arise as a consequence of the automatized mechanisms by which humans retrieve words to produce sentences. Four experiments show that, when describing events, speakers tend to mention people who are more like them first and, thus, tend to highlight the perspectives of their own social groups. This ‘like me’ effect was seen in speakers from multiple demographic groups, in both English and Chinese speakers and in both first- and second-language English speakers. Psycholinguistic manipulations pinpoint that the bias is caused by greater accessibility in memory of words that refer to in-group than out-group members. These data provide a new cognitive explanation for why people produce biased language and highlight how detailed cognitive theories can have social implications.
Prevention and treatment of peri-implant fibrosis by functionally inhibiting skeletal cells expressing the leptin receptor
Authors: Vincentius Jeremy Suhardi, Anastasia Oktarina, Mohammed Hammad, Yingzhen Niu, Qingdian Li, Andrew Thomson, Juan Lopez, Jason McCormick, Ugur M. Ayturk, Matthew B. Greenblatt, Lionel B. Ivashkiv, Mathias P. G. Bostrom, Xu Yang
Journal: Nature Biomedical Engineering (2024)
Cranioencephalic functional lymphoid units in glioblastoma
Authors: Celia Dobersalske, Laurèl Rauschenbach, Yichao Hua, Christoph Berliner, Anita Steinbach, Anika Grüneboom, Konstantinos D. Kokkaliaris, Dieter H. Heiland, Pia Berger, Sarah Langer, Chin L. Tan, Martin Stenzel, Somaya Landolsi, Flora Weber, Marvin Darkwah Oppong, Rudolf A. Werner, Hanah Gull, Thomas Schröder, Thomas Linsenmann, Andreas K. Buck, Matthias Gunzer, Martin Stuschke, Kathy Keyvani, Michael Forsting, Martin Glas, Jonathan Kipnis, Dennis A. Steindler, Hans Christian Reinhardt, Edward W. Green, Michael Platten, Alpaslan Tasdogan, Ken Herrmann, Florian Rambow, Igor Cima, Ulrich Sure, Björn Scheffler
Journal: Nature Medicine (2024)

The ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to report that the cranial bone (CB) marrow, in juxtaposition to treatment-naive glioblastoma tumors, harbors active lymphoid populations at the time of initial diagnosis. Clinical and anatomical imaging, single-cell molecular and immune cell profiling and quantification of tumor reactivity identified CD8
Prostacyclin Synthase Deficiency Leads to Exacerbation or Occurrence of Endothelium-Dependent Contraction and Causes Cardiovascular Disorders Mainly via the Non-TxA <sub>2</sub> Prostanoids/TP Axis
Authors: Jiahui Ge, Yingbi Zhou, Hui Li, Ruhui Zeng, Kaiqi Xie, Jing Leng, Xijian Chen, Gang Yu, Xinya Shi, Yineng Xu, Dong He, Pi Guo, Yongyin Zhou, Hongjun Luo, Wenhong Luo, Bin Liu
Journal: Circulation Research (2024)

BACKGROUND: Prostaglandin I 2 synthesized by endothelial COX (cyclooxygenase) evokes potent vasodilation in some blood vessels but is paradoxically responsible for endothelium-dependent constriction (EDC) in others. Prostaglandin I 2 production and EDC may be enhanced in diseases such as hypertension. However, how PGIS (prostaglandin I 2 synthase) deficiency affects EDC and how this is implicated in the consequent cardiovascular pathologies remain largely unknown. METHODS: Experiments were performed with wild-type, Pgis knockout ( Pgis − / − ) and Pgis /thromboxane-prostanoid receptor gene ( Tp ) double knockout ( Pgis − / − Tp − / − ) mice and Pgis − / − mice transplanted with unfractionated wild-type or Cox-1 − / − bone marrow cells, as well as human umbilical arteries. COX-derived prostanoids were measured by high-performance liquid chromatography-mass spectrometry. Vasomotor responses of distinct types of arteries were assessed by isometric force measurement. Parameters of hypertension, vascular remodeling, and cardiac hypertrophy in mice at different ages were monitored. RESULTS: PGF 2α , PGE 2 , and a trace amount of PGD 2 , but not thromboxane A 2 (TxA 2 ), were produced in response to acetylcholine in Pgis − / − or PGIS-inhibited arteries. PGIS deficiency resulted in exacerbation or occurrence of EDC ex vivo and in vivo. Endothelium-dependent hyperpolarization was unchanged, but phosphorylation levels of eNOS (endothelial nitric oxide synthase) at Ser1177 and Thr495 were altered and NO production and the NO-dependent relaxation evoked by acetylcholine were remarkably reduced in Pgis − / − aortas. Pgis − / − mice developed high blood pressure and vascular remodeling at 16 to 17 weeks and subsequently cardiac hypertrophy at 24 to 26 weeks. Meanwhile, blood pressure and cardiac parameters remained normal at 8 to 10 weeks. Additional ablation of TP (TxA 2 receptor) not only restrained EDC and the downregulation of NO signaling in Pgis − / − mice but also ameliorated the cardiovascular abnormalities. Stimulation of Pgis − / − vessels with acetylcholine in the presence of platelets led to increased TxA 2 generation. COX-1 disruption in bone marrow–derived cells failed to affect the development of high blood pressure and vascular remodeling in Pgis − / − mice though it largely suppressed the increase of plasma TxB 2 (TxA 2 metabolite) level. CONCLUSIONS: Our study demonstrates that the non-TxA 2 prostanoids/TP axis plays an essential role in mediating the augmentation of EDC and cardiovascular disorders when PGIS is deficient, suggesting TP as a promising therapeutic target in diseases associated with PGIS insufficiency.
AMPK Attenuation of β-Adrenergic Receptor-Induced Cardiac Injury via Phosphorylation of β-Arrestin-1-ser330
Authors: Mingming Zhao, Ning Cao, Huijun Gu, Jiachao Xu, Wenli Xu, Di Zhang, Tong-You Wade Wei, Kang Wang, Ruiping Guo, Hongtu Cui, Xiaofeng Wang, Xin Guo, Zhiyuan Li, Kangmin He, Zijian Li, Youyi Zhang, John Y.-J. Shyy, Erdan Dong, Han Xiao
Journal: Circulation Research (2024)

β-adrenergic receptor (β-AR) overactivation is a major pathological cue associated with cardiac injury and diseases. AMPK (AMP-activated protein kinase), a conserved energy sensor, regulates energy metabolism and is cardioprotective. However, whether AMPK exerts cardioprotective effects via regulating the signaling pathway downstream of β-AR remains unclear.
Deciphering 3D periodontal fibroblast-macrophage crosstalk in bioactive nanoparticle-guided immunomodulation for treating traumatic dental avulsion
Authors: Hadagalu Revana Siddappa Rajeshwari, Emily Bishop, Aiman Ali, Anil Kishen
Journal: Bioactive Materials (2024)

Prolonged extra-oral period in dental avulsion is often associated with loss of viability of Periodontal fibroblasts (PDLF) and increased risk of ankylosis. Root surface treatment with bioactive agents to reduce the risk of ankylosis can be a potential strategy. The objective of the study was to investigate the impact of an engineered chitosan nanoparticles (CSNP), photosensitizer Rose Bengal (RB) functionalized CSNP (CSRB) and sustained dexamethasone (CSDEX) releasing CSNP for application in management of delayed replantation of avulsed teeth. The 3D PDLF-macrophage (Mϕ) collagen model was developed and exposed to LPS, MCSF, RANKL with and without CSDEX/CSNP. Immunofluorescence and cytokine analysis was done at 2 and 7 days to assess cellular interactions. Maxillary right incisors in male Wistar rats were extracted, exposed to extraoral dry or LPS for 1 h and treated with or without CSDEX/CSRB for 1 min before replantation. Rats were euthanized after 21 days for micro-CT, TRAP, and immunofluorescence analysis. CSDEX/CSNP treatment in 3D model significantly reduced CD80, NFATc1, STAT6 and increased CD206 and periostin expression (
Bone marrow niches for hematopoietic stem cells
Authors: Ana Luísa Pereira, Serena Galli, César Nombela‐Arrieta
Journal: HemaSphere (2024)

Abstract Hematopoietic stem cells (HSCs) are the cornerstone of the hematopoietic system. HSCs sustain the continuous generation of mature blood derivatives while self‐renewing to preserve a relatively constant pool of progenitors throughout life. Yet, long‐term maintenance of functional HSCs exclusively takes place in association with their native tissue microenvironment of the bone marrow (BM). HSCs have been long proposed to reside in fixed and identifiable anatomical units found in the complex BM tissue landscape, which control their identity and fate in a deterministic manner. In the last decades, tremendous progress has been made in the dissection of the cellular and molecular fabric of the BM, the structural organization governing tissue function, and the plethora of interactions established by HSCs. Nonetheless, a holistic model of the mechanisms controlling HSC regulation in their niche is lacking to date. Here, we provide an overview of our current understanding of BM anatomy, HSC localization, and crosstalk within local cellular neighborhoods in murine and human tissues, and highlight fundamental open questions on how HSCs functionally integrate in the BM microenvironment.
Improvement of Therapeutic Effect via Inducing Non‐Apoptotic Cell Death Using mRNA‐Protection Nanocage
Authors: Seoyoung Kim, Seongchan Kim, Sojin Kim, Nan‐Ee Lee, Soo‐Hwan Lee, Hyunkyung Kim, Hyojin Lee
Journal: Advanced Healthcare Materials (2024)

Abstract Necroptosis, a cell death mechanism with the characteristics of both apoptosis and necrosis, is proposed as a promising therapeutic approach for cancer therapy. Induction of necroptosis for cancer therapy may be possible through the regulation of the expression of a key factor gene receptor‐interacting protein kinase‐3 (RIPK3) via in vitro transcription (IVT) mRNA delivery. However, mRNA is susceptible to degradation and has a low delivery efficiency, which highlights the requirement of a proper delivery vehicle for intracellular delivery. Therefore, a new mRNA delivery system based on the nanostructured silica nanoparticles, termed mRNA‐protective nanocage (mPN) has been developed. High‐efficiency expression of RIPK3 and induction of necroptosis is achieved through delivery of RIPK3 IVT mRNA with mPN in vitro and in vivo models. Importantly, the mPN carrying RIPK3 mRNA distributed locally in tumors upon intravascular injection, and successfully induced necroptosis and immune cell infiltration, a hallmark of necroptosis. the suppression of tumor growth in a murine cancer model, demonstrating the synergistic effect of RIPK3 mRNA‐ and immune cell‐mediated therapy is also observed. These findings suggest the potential for anticancer therapy through necroptosis induction and provide a strategy for the development of mRNA‐based nanomedicine.
Emulsion‐Based Multi‐Phase Integrated Microbeads with Inner Multi‐Interface Structure Enable Dual‐Modal Imaging for Precision Endovascular Embolization
Authors: Zhihua Li, Man Huang, Yingnan Li, Yongchao Wang, Yutao Ma, Le Ma, Hongliang Jiang, To Ngai, Jianbo Tang, Qiongyu Guo
Journal: Advanced Healthcare Materials (2024)

Abstract Microsphere‐based embolic agents have gained prominence in transarterial embolization (TAE) treatment, a critical minimally invasive therapy widely applied for a variety of diseases such as hypervascular tumors and acute bleeding. However, the development of microspheres with long‐term, real‐time, and repeated X‐ray imaging as well as ultrasound imaging remains challenging. In this study, emulsion‐based dual‐modal imaging microbeads with a unique internal multi‐interface structure is developed for TAE treatment. The embolic microbeads are fabricated from a solidified oil‐in‐water (O/W) emulsion composed of crosslinked CaAlg‐based aqueous matrix and dispersed radiopaque iodinated oil (IO) droplets through a droplet‐based microfluidic fabrication method. The CaAlg‐IO microbeads exhibit superior X‐ray imaging visibility due to the incorporation of exceptionally high iodine level up to 221 mgI mL −1 , excellent ultrasound imaging capability attributed to the multi‐interface structure of the O/W emulsion, great microcatheter deliverability thanks to their appropriate biomechanical properties and optimal microbead density, and extended drug release behavior owing to the biodegradation nature of the embolics. Such an embolic agent presents a promising emulsion‐based platform to utilize multi‐phased structures for improving endovascular embolization performance and assessment capabilities.
PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial
Authors: Fahong Li, Lihong Qu, Yanhong Liu, Xiaoping Wu, Xun Qi, Jinyu Wang, Haoxiang Zhu, Feifei Yang, Zhongliang Shen, Yifei Guo, Yongmei Zhang, Jie Yu, Richeng Mao, Qiran Zhang, Fengdi Zhang, Liang Chen, Yuxian Huang, Xinxin Zhang, Qingxing Li, Wenhong Zhang, Jiming Zhang
Journal: Journal of Hepatology (2024)
Diversity and Inclusivity in Rheumatology Publications
Authors: Amr H. Sawalha, Kelli D. Allen, Candace H. Feldman, S. Sam Lim, Andras Perl, Daniel H. Solomon, Edith M. Williams
Journal: Arthritis & Rheumatology (2024)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis
Authors: Suhua Jiang, Mengyun Cai, Dingru Li, Xiangping Chen, Xiaoqian Chen, Qitao Huang, Caimei Zhong, Xiufeng Zheng, Dan Zhou, Zhiyan Chen, Lin Zhang, Jessica YL Ching, Ailing Chen, Shaoxia Lu, Lifang Zhang, Ling Hu, Yan Liao, Ying Li, Zhihua He, Jingjing Wu, Huiyi Huo, Yongqi Liang, Wanwen Li, Yanli Zou, Wei Luo, Siew C Ng, Francis KL Chan, Xia Chen, Yuhua Deng
Journal: Gut (2024)

The specific breast milk-derived metabolites that mediate host-microbiota interactions and contribute to the onset of atopic dermatitis (AD) remain unknown and require further investigation.
Prevalence of Endoscopically Curable Low-Risk Cancer amongst Large (≥20mm) Non-Pedunculated Polyps in the Right Colon
Authors: Julia L Gauci, Anthony Whitfield, Renato Medas, Clarence Kerrison, Francesco Vito Mandarino, David Gibson, Timothy O'Sullivan, Oliver Cronin, Sunil Gupta, Brian Lam, Varan Perananthan, Luke Hourigan, Simon Zanati, Rajvinder Singh, Spiro Raftopoulos, Alan Moss, Gregor Brown, Amir Klein, Lobke Desomer, David J Tate, Steven J Williams, Eric Y Lee, Nicholas Burgess, Michael J Bourke
Journal: Clinical Gastroenterology and Hepatology (2024)
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial
Authors: Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C Nordström, Michael T Nurmohamed, Anna Rudin, Mikkel Østergaard, Espen A Haavardsholm, Kim Hørslev-Petersen, Till Uhlig, Tuulikki Sokka-Isler, Bjorn Gudbjornsson, Gerdur Grondal, Giulia Frazzei, Jeroen Christiaans, Gertjan Wolbink, Theo Rispens, Jos W R Twisk, Ronald F van Vollenhoven
Journal: Annals of the Rheumatic Diseases (2024)

To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active conventional treatment (ACT).
Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus-related hepatocellular carcinoma
Authors: Sung Won Chung, Hyun Jun Um, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
Journal: Clinical Gastroenterology and Hepatology (2024)
Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related disease
Authors: Guy Katz, Cory Perugino, Zachary S Wallace, Bohang Jiang, Thomas Guy, Grace A McMahon, Isha Jha, Yuqing Zhang, Hang Liu, Ana D Fernandes, Shiv S Pillai, John Patterson Atkinson, Alfred Hyoungju Kim, John H Stone
Journal: Annals of the Rheumatic Diseases (2024)

Hypocomplementaemia is common in patients with IgG4-related disease (IgG4-RD). We aimed to determine the IgG4-RD features associated with hypocomplementaemia and investigate mechanisms of complement activation in this disease.
Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod
Authors: Fernando Magro, Laurent Peyrin-Biroulet, Bruce E. Sands, Silvio Danese, Vipul Jairath, Martina Goetsch, Abhishek Bhattacharjee, Joseph Wu, Diogo Branquinho, Irene Modesto, Brian G. Feagan
Journal: Clinical Gastroenterology and Hepatology (2024)

Background & AimsHistologic remission, a potentially important treatment target in ulcerative colitis (UC), is associated with favorable long-term outcomes. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post-hoc analysis of the ELEVATE UC program evaluated the efficacy of etrasimod according to histologic and composite (histologic/endoscopic/symptomatic) endpoints and examined their prognostic value.MethodsPatients with moderately to severely active UC were randomized 2:1 to once-daily oral etrasimod 2 mg or placebo. Histologic and composite endpoints, including disease clearance (endoscopic/histologic/symptomatic remission), were assessed at Weeks 12 (ELEVATE UC 52; ELEVATE UC 12) and 52 (ELEVATE UC 52). Logistic regressions examined associations between baseline and Week 12 histologic/composite endpoints and Week 52 outcomes.ResultsAt Weeks 12 and 52, significant improvements with etrasimod vs placebo were observed in histologic/composite outcomes, including endoscopic improvement-histologic remission and disease clearance. The proportion of patients treated with etrasimod achieving clinical remission at Week 52 was higher among those with disease clearance at Week 12 vs those without disease clearance (73.9% [17/23] vs 28.3% [71/251]). Histologic improvement and endoscopic improvement at Week 12 were moderately and strongly associated with clinical remission at Week 52 (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.27–4.41; and OR, 6.36; 95% CI, 3.47–11.64, respectively). Histologic remission and endoscopic improvement at Week 12 were strongly associated with endoscopic improvement-histologic remission at Week 52 (OR, 3.21; 95% CI, 1.70–6.06 and OR, 5.47; 95% CI, 2.89–10.36, respectively).ConclusionsEtrasimod was superior to placebo for achievement of stringent histologic and composite endpoints.ClinicalTrials.gov, Number: NCT03945188; ClinicalTrials.gov, Number: NCT03996369.Graphical abstract
Orchestrated Metal-coordinated Carrier-free Celastrol Hydrogel Intensifies T Cell Activation and Regulates Response to Immune Checkpoint Blockade for Synergistic Chemo-immunotherapy
Authors: Linying Wu, Wenmin Pi, Xuemei Huang, Luping Yang, Xiang Zhang, Jihui Lu, Shuchang Yao, Xiaoyu Lin, Xinru Tan, Zhixia Wang, Penglong Wang
Journal: Biomaterials (2024)